We specialise in systematic reviews of biomedical science and have the expertise to understand novel technologies and their terminology that are a challenge for health research investigators. We have particular expertise of preclinical models (human cell culture, organoids, 3D spheroids and patient derived xenografts), helping clients understand which are the best validated models for their needs.
Despite promising preclincial studies many 'landmark' findings in biomedical science cannot be reproduced, contributing to the high failure rate of new drugs reaching the clinic.
Our solution is to provide evidence-based decision making using a formal, unbiased process that has been a feature of clinical science appraisal, for decades. We can help identify weaknesses and provide solutions.
There are 4 stages to our process:
1. We work with our clients to define the research question.
2. We help the client decide whether they require a full systematic review or a tailored evaluation of the evidence
3. We help the client decide what type of evaluation is required. This could be:
- In-house validation tools for model, marker or tissue validity
- The statistical reliability of results
- Clinical study risk of bias
- Preclinical study risk of bias
4. A report is compiled which presents the evidence in a transparent manner. We provide layered evidence; a summary evidence table backed by detailed data and methodology. We use a traffic light system outlining strengths, weaknesses and evidence gaps. More informed decisions can then be made on potential risks and benefits of investments under consideration.